Clinical trial · Interventional
Thromboprophylaxis After Surgery for Gynecologic Malignancy in China
Effectiveness and Safety of Thromboprophylaxis After Surgery for Gynecologic Malignancy in China
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Venous thromboembolism (VTE) is an important cause of post-operative morbidity and mortality in women undergoing surgery for gynecologic malignancies. Although the benefit of thromboprophylaxis in reduction of post-operative VTE events after surgery for gynecologic cancers has been well documented around the world, the evidence for Chinese women is rare. The investigators designed this prospective and randomized study to assess the benefit of pharmacologic prophylaxis for patients received surgical treatment for gynecologic malignancies in China.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Argatroban | — | UNRESOLVED | — |
| Gynecologic Neoplasms | Female Reproductive System Neoplasm | ALIAS | 0.90 |
| Low Molecular Weight Heparin | — | UNRESOLVED | — |
| Venous Thromboembolism | — | UNRESOLVED | — |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Argatroban | Drug | — | UNRESOLVED |
| LMWH | Drug | — | UNRESOLVED |
| s-LMWH | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- type
- EXPERIMENTAL
- label
- s-LMWH
- description
- 2125 I.U. subcutaneous injection for 5-10 days
- interventionNames
- Drug: s-LMWH
- type
- ACTIVE_COMPARATOR
- label
- LMWH
- description
- 4250 I.U. subcutaneous injection for 5-10 days
- interventionNames
- Drug: LMWH
- type
- EXPERIMENTAL
- label
- Argatroban
- description
- 20mg, injection for 5-10 days
- interventionNames
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 16 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * Patients of ovarian cancer, cervix cancer or endometrial cancer; * Age ≤ 70 years; female, Chinese women; * Initial treatment is surgery; * Laboratory tests: WBC ≥ 4×10(9)/L, NEU ≥ 2×10(9)/L, PLT ≥ 100×10(9)/L, serum bilirubin ≤ 1.5 times the upper limit of normal, transaminase ≤ 1.5 times the upper limit of normal, BUN, Cr ≤ normal * No prior pharmacologic prophylaxis; * Provide written informed consent. Exclusion Criteria: * PLT ≤ 75×10(9)/L * Vascular injury * History of thrombosis * Liver and kidney dysfunction * Concurrently participating in other clinical trials * Unable or unwilling to sign informed consents; * Unable or unwilling to abide by protocol.
References
Publications (0)
Data not yet available